Cognitive Enhancement: Pharmacologic, Environmental and Genetic Factors
Format: PDF / Kindle (mobi) / ePub
Cognitive Enhancement: Pharmacologic, Environmental and Genetic Factors addresses the gap that exists in research on the topic, gathering multidisciplinary knowledge and tools that help the reader understand the basics of cognitive enhancement. It also provides assistance in designing procedures and pharmacological approaches to further the use of novel cognitive enhancers, a field that offers potential benefit to a variety of populations, including those with neurologic and psychiatric disorders, mild aging-related cognitive impairment, and those who want to improve intellectual performance.
The text builds on our knowledge of the molecular/cellular basis of cognitive function, offering the technological developments that may soon enhance cognition. Separate sections cover enhancement drugs, environmental conditions, and genetic factors in terms of both human and animal studies, including both healthy/young and aging/diseased individuals.
- Provides a multidisciplinary knowledge, enabling a further understanding of cognitive enhancement
- Offers coverage of the pharmacologic, environmental, and genetic factors relevant to the topic
- Discusses cognitive enhancement from the perspective of both healthy and diseased or aging populations
- Topics are discussed in terms of both human and animal studies
areas while also promoting attention sustainability (Davidson et al., 2003). Different studies also emphasized the role of meditation as a mental process that modulates plasticity in neural circuits commonly associated with attention (Davidson and Lutz, 2008). Functional magnetic resonance imaging studies also demonstrated a reduction of neural responses in widespread brain regions that are linked to conceptual processing, which suggests enhanced neural efficiency, probably via improved sustained
legitimate and should be addressed in future studies. Conclusions The term “cognitive enhancement” is associated with use of drugs or devices for non–health-related enhancement of cognition. Most of these technologies have either been established in animal models or through a history of use in humans. While there are many unanswered questions about specific aspects of existing cognitive enhancers (e.g., properties, prevalence, modalities, reasons for use, likely future developments) the
its relevance to understanding and treating depression. Pharmacol. Ther. 2011;132:242–267. Pulipparacharuvil S, Renthal W, Hale C.F, Taniguchi M, Xiao G, Kumar A, et al. Cocaine regulates MEF2 to control synaptic and behavioral plasticity. Neuron. 2008;59:621–633. Ramírez-Rodríguez G, Ocaña-Fernández M.A, Vega-Rivera N.M, Torres-Pérez O.M, Gómez-Sánchez A, Estrada-Camarena E, Ortiz-López L. Environmental enrichment induces neuroplastic changes in middle age female BalbC mice and increases the
cognitive function is impaired, even if the pathogenic alteration is not fully understood. Therefore, investigations on mechanisms leading to cognitive enhancement will have both basic and translational interest. Genetic studies on animal models have already offered a catalog of molecular alterations that result in enhanced cognition (Lee and Silva, 2009). Notably, most of these genetic changes can be related more or less directly with the process of synaptic plasticity, particularly long-term
Synaptic Plasticity Treatment Strategies The Drugs Do Not Work: What Is Failing in AD Therapies? The Future of Cognitive Enhancement in AD Concluding Remarks Chapter 10. Pharmacological Treatment of Cognitive Dysfunction in Neuropsychiatric Disorders Introduction Posttraumatic Stress Disorder Attention Deficit/Hyperactivity Disorder Major Depressive Disorder Schizophrenia Bipolar Disorder Chapter 11. Cognitive Enhancement in Humans Introduction Pharmaceuticals Nutrition Physical